Close Menu
    Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    Infectious Diseases

    FDA Authorizes Marketing of First Diagnostic Test for Zika Virus Antibodies

    By Global Biodefense StaffMay 23, 2019
    Neural Impact of Zika Virus Infection
    Share
    Facebook LinkedIn Reddit Email

    The marketing authorization does not impact the availability of the 14 other Zika nucleic acid diagnostics available under EUAs.

    Today, the U.S. Food and Drug Administration authorized marketing  of a diagnostic test to detect Zika virus immunoglobulin (IgM) antibodies in human blood to InBios International, Inc.

    The ZIKV Detect 2.0 IgM Capture ELISA is the first Zika diagnostic test the FDA has allowed to be marketed in the U.S.; previously, tests for detecting Zika virus IgM antibodies—including the ZIKV Detect 2.0 IgM Capture ELISA—had been authorized only for emergency use under the FDA’s Emergency Use Authorization (EUA) authority.

    The FDA reviewed data for the ZIKV Detect 2.0 IgM Capture ELISA test through the de novo premarket review pathway, a regulatory pathway for low-to-moderate-risk devices of a new type. Along with this authorization, the FDA is establishing criteria, called special controls, that determine the requirements for demonstrating accuracy, reliability and effectiveness of tests intended to identify Zika virus antibodies.

    These special controls, when met along with general controls, provide a reasonable assurance of safety and effectiveness for tests of this type. This action also creates a new regulatory classification, which means that subsequent devices of the same type with the same intended use may go through the FDA’s 510(k) pathway, whereby devices can obtain clearance by demonstrating substantial equivalence to a predicate device.

    U.S. FDA

    Editor Pick Emergency Use Authorization Emerging Threats Zika
    Share. Facebook LinkedIn Reddit Email
    Previous ArticleDaiichi Sankyo Apologizes for Not Meeting Vaccine Production Milestone for Pandemic Preparedness
    Next Article As Rates of STDs Rise in America, HHS Seeks Input on Developing Federal Action Plan

    Related Stories

    Ontario Supporting $165M Investment to Secure Critical PPE Supply

    December 2, 2023

    Black Death Impact on Microbiome May Have Contributed to Modern-Day Chronic Diseases

    November 29, 2023

    Valley Fever: An Invisible Killer Expands Its Range in the American West

    November 17, 2023

    Virginia Tech Lab Selected for National Partnership to Fight Emerging Diseases

    November 14, 2023
    News Scan

    Biodefense Headlines – 30 November 2023

    News Scan November 30, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include the largest ever outbreak of mpox in the DRC; launch of National Wastewater Surveillance Program dashboard; low uptake of COVID-19 boosters and flu vaccines;…

    Upcoming Events

    Dec 5
    10:45 am - 3:00 pm EST

    Meeting the Moment: Biodefense Policy, Procurement, and Public Health

    Dec 6
    Virtual Event Virtual Event
    6:00 am - 7:00 am EST

    AMR One Health Priority Research Agenda: Transmission

    Mar 12
    Virtual Event Hybrid Event
    March 12, 2024 - March 17, 2024

    2024 Fungal Genetics Conference

    Mar 21
    March 21, 2024 - March 23, 2024

    ASPPH 2024 Annual Meeting

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    News on pathogens and preparedness for public health emergencies

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.